Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
Primary result · ALT improvement >30% or normalizationResult — go to the resultAdjusted odds ratio 1.51 95% CI 1.38–1.64Authors' conclusion
In patients with T2DM, treatment with canagliflozin vs placebo resulted in improvements in liver biochemistry and metabolism and might beneficially affect liver fibrosis.
Study context
- Population
- Patients with T2D and high cardiovascular risk; mean age 62 years, mean diabetes duration 13.5 years, 64.2% male; 88.5% with MAFLD by hepatic steatosis index
- Participants
- 10,131 patients
- Comparison
- Canagliflozin vs placebo once daily
- Primary endpoint
- Composite of:
- ALT improvement >30%
- ALT normalization
- Follow-up
- Median 2.4 years
Methodological detailspost hoc, double-blind
- Post hoc
- Double-blind
Primary result
ALT improvement >30% or normalization
Adjusted odds ratio
1.51
95% CI 1.38–1.64
P < 0.001
By group
Canagliflozinvs Placebo
aOR 1.51 (95% CI 1.38–1.64); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | Canagliflozin | Placebo | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Weight reduction >10% · within 6 years | 12.7% | 4.1% | 3.45 (2.91–4.10) | P < 0.001 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Noninvasive tests of fibrosis
- Canagliflozin led to improvements in some noninvasive fibrosis tests (NFS, APRI, FNI)
Original publication
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. J Clin Endocrinol Metab. Published 7 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →